Observation of the Efficacy of Nabulizumab Combined with Anilotinib in Atage Ⅲb～Ⅳ NSCLC and the Effect on the Expression of miR-1269 and miR-204-5p
Objective To investigate the effect of nivolumab combined with anlotinib on the expression of microRNA-1269(miR-1269)and miR-204-5p in patients with stage Ⅲb～Ⅳ non-small cell lung cancer(NSCLC).Methods 82 patients with stage Ⅲb to Ⅳ NSCLC were selected,and the patients were allocated into the control group and the observation group,41 ca-ses in each,using the random number table method,the control group was treated with anilotinib,and the observation group was treated with navulizumab on the basis of the control group.The curative effect,the expression levels of tumor markers carcinoem-bryonic antigen(CEA),cytokeratin 19 fragment 21-1(CYFRA21-1),miR-1269,miR-204-5p and the incidence of adverse reac-tions were compared between the 2 groups.Results The disease control rate of the observation group after treatment(87.80％,36/41)was obviously higher than that of the control group(68.29％,28/41)(x2=4.556,P=0.033);compared with before treatment,the levels of CEA,CYFRA21-1,and miR-1269 in the observation group and the control group were obviously reduced after treatment,while the level of miR-204-5p was obviously increased(P＜0.05);after treatment,compared with the control group,the levels of CEA,CYFRA21-1,and miR-1269 in the observation group were obviously reduced,while the level of miR-204-5p was obviously increased(P＜0.05);there was no statistically obvious difference in the incidence of adverse reactions be-tween the observation group and the control group(P＞0.05).Conclusion Nivolumab combined with anlotinib can reduce the level of tumor markers and regulate the expression of miR-1269 and miR-204-5p in patients with stage Ⅲb-Ⅳ NSCLC.
NETL
NSTL
万方数据
